<DOC>
	<DOCNO>NCT02029066</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics solamargine SR-T100 gel . As safety parameter , adverse event , vital sign ( blood pressure , heart rate , body temperature ) record .</brief_summary>
	<brief_title>Pharmacokinetic Study Solamargine Patients With Actinic Keratosis</brief_title>
	<detailed_description>In study period , single dose 2 g topical SR-T100 gel ( contain 2.3 % solamargine Solanum undatum plant extract ) 100 cm2 skin area cover occlusive dressing administer . Sampling Time Schedule : 0.5 , 1 , 1.5 , 2 , 2.5 , 3 , 4 , 5 , 6 , 8 , 12 , 16 , 20 , 24 , 36 hour dose .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>1 . Male female 20 year age . 2 . Patient AK lesion locate within 100 cm2 contiguous noncontiguous treatment area . 3 . Patient least one clinical confirm AK lesion within select treatment area . 1 . Patient use follow treatment within 4 week prior study treatment initiation : immunomodulators immunosuppressive therapy , interferon , cytotoxic drug . 2 . Patient treat topical 5FU , diclofenac gel , imiquimod , ingenol mebutate , corticosteroid , retinoids , masoprocol treatment area within 4 week prior study treatment initiation . 3 . Patient receive cryodestruction , chemodestruction , curettage , photodynamic therapy , surgical excision treatment area within 4 week prior study treatment initiation . 4 . Patient receive follow treatment treatment area 6 month study treatment initiation : psoralen plus UVA therapy , UVB therapy , laser abrasion , dermabrasion , chemical peel . 5 . Patient use topical preparation , sunscreen , moisturizers , body oil , alpha beta hydroxyl acid , treatment area within 24 hour study course . 6 . Use medication , include counter product , herb medicine dietary supplement vitamin , would interfere study result , within one week study course . 7 . Patient know hypersensitive study medication . 8 . Female pregnant , breastfeed consider become pregnant study . 9 . Donation 500 ml blood past 3 month prior dose donation 250 ml blood past 2 month prior dose . 10 . Patient use investigational drug within past 30 day enrollment . 11 . Patient dermatological disease and/or condition , atopic dermatitis , basal cell carcinoma , eczema , psoriasis , rosacea , squamous cell carcinoma , melanoma , possible confound skin condition treatment surround area ( 5 cm distance treatment area ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>actinic keratosis</keyword>
	<keyword>SR-T100</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>